Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. doi: 10.1128/AAC.03328-14. Epub 2014 Sep 8.

The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.

Author information

1
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
2
Biota Pharmaceuticals Inc., Notting Hill, Vic., Australia.
3
Institute of Biochemistry, Center for Structural and Cell Biology in Medicine, University of Lübeck, Lübeck, Germany.
4
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium johan.neyts@rega.kuleuven.be.

Abstract

Antivirals against enterovirus 71 (EV71) are urgently needed. We demonstrate that the novel enteroviral protease inhibitor (PI) SG85 and capsid binder (CB) vapendavir efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C. The PI rupintrivir, the CB pirodavir, and the host-targeting compound enviroxime, which were included as reference compounds, also inhibited the replication of all isolates. Remarkably, the CB compound pleconaril was devoid of any anti-EV71 activity. An in silico docking study revealed that pleconaril-unlike vapendavir and pirodavir-lacks essential binding interactions with the viral capsid. Vapendavir and SG85 (or analogues) should be further explored for the treatment of EV71 infections. The data presented here may serve as a reference when developing yet-novel inhibitors.

PMID:
25199773
PMCID:
PMC4249361
DOI:
10.1128/AAC.03328-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center